Comparative Pharmacology
Head-to-head clinical analysis: AMOXICILLIN PEDIATRIC versus PENICILLIN 2.
Peer-Reviewed Evidence
Head-to-head clinical analysis: AMOXICILLIN PEDIATRIC versus PENICILLIN 2.
AMOXICILLIN PEDIATRIC vs PENICILLIN-2
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Amoxicillin is a semisynthetic penicillin antibiotic that inhibits bacterial cell wall synthesis by binding to penicillin-binding proteins (PBPs). It blocks the transpeptidation step in peptidoglycan cross-linking, leading to cell lysis and death.
Inhibits bacterial cell wall synthesis by binding to penicillin-binding proteins (PBPs), inhibiting transpeptidase activity, and activating autolytic enzymes.
250-500 mg orally every 8 hours or 500-875 mg orally every 12 hours for adults.
250 mg orally every 6 hours or 500 mg orally every 8 hours for mild to moderate infections; intravenous dosing: 1-2 million units every 4-6 hours.
None Documented
None Documented
Terminal elimination half-life: 1-1.5 hours in children with normal renal function; prolonged to 7-21 hours in anuria.
30-60 minutes; prolonged in renal impairment (up to 10 hours in anuria)
Renal: 60-80% unchanged via glomerular filtration and tubular secretion; biliary: minor (<10%); fecal: <5%.
Renal: 60-80% unchanged; biliary/fecal: minor (10-20%)
Category A/B
Category C
Penicillin Antibiotic
Penicillin Antibiotic